Urogen Pharma (URGN) to Release Quarterly Earnings on Thursday

Urogen Pharma (NASDAQ:URGN) is projected to post its Q2 2026 results before the market opens on Thursday, August 6th. Analysts expect Urogen Pharma to post earnings of ($0.2650) per share and revenue of $63.5460 million for the quarter. Interested persons can find conference call details on the company’s upcoming Q2 2026 earning report page for the latest details on the call scheduled for Wednesday, August 5, 2026 at 10:00 AM ET.

Urogen Pharma (NASDAQ:URGN) last issued its quarterly earnings data on Thursday, May 7th. The company reported ($0.47) earnings per share (EPS) for the quarter, topping the consensus estimate of ($0.48) by $0.01. The firm had revenue of $50.96 million for the quarter, compared to analyst estimates of $44.83 million. On average, analysts expect Urogen Pharma to post $-1 EPS for the current fiscal year and $2 EPS for the next fiscal year.

Urogen Pharma Stock Performance

URGN opened at $40.45 on Thursday. The business’s fifty day moving average is $34.57 and its two-hundred day moving average is $26.07. The company has a market cap of $1.97 billion, a price-to-earnings ratio of -14.71 and a beta of 1.56. Urogen Pharma has a one year low of $15.86 and a one year high of $43.93.

Insider Buying and Selling

In other Urogen Pharma news, insider Mark Schoenberg sold 10,000 shares of the firm’s stock in a transaction on Thursday, July 9th. The stock was sold at an average price of $40.00, for a total transaction of $400,000.00. Following the completion of the transaction, the insider owned 119,763 shares of the company’s stock, valued at approximately $4,790,520. This trade represents a 7.71% decrease in their ownership of the stock. The transaction was disclosed in a filing with the SEC, which is accessible through this link. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. In the last 90 days, insiders sold 25,222 shares of company stock worth $892,661. 4.80% of the stock is currently owned by corporate insiders.

Institutional Trading of Urogen Pharma

Several institutional investors and hedge funds have recently made changes to their positions in URGN. Russell Investments Group Ltd. boosted its stake in shares of Urogen Pharma by 1,594.4% during the third quarter. Russell Investments Group Ltd. now owns 3,321 shares of the company’s stock valued at $66,000 after acquiring an additional 3,125 shares during the last quarter. Osaic Holdings Inc. raised its stake in Urogen Pharma by 491.2% in the 2nd quarter. Osaic Holdings Inc. now owns 3,695 shares of the company’s stock valued at $50,000 after purchasing an additional 3,070 shares during the last quarter. Tower Research Capital LLC TRC lifted its holdings in Urogen Pharma by 422.0% in the 2nd quarter. Tower Research Capital LLC TRC now owns 6,891 shares of the company’s stock valued at $94,000 after purchasing an additional 5,571 shares in the last quarter. Creative Planning purchased a new position in Urogen Pharma in the 3rd quarter valued at about $208,000. Finally, Orion Porfolio Solutions LLC purchased a new position in Urogen Pharma in the 3rd quarter valued at about $220,000. 91.29% of the stock is currently owned by hedge funds and other institutional investors.

Wall Street Analyst Weigh In

A number of research analysts have recently weighed in on the company. Weiss Ratings restated a “sell (d-)” rating on shares of Urogen Pharma in a research report on Friday, July 17th. LADENBURG THALM/SH SH initiated coverage on shares of Urogen Pharma in a research note on Monday, May 11th. They issued a “buy” rating and a $43.00 price objective on the stock. The Goldman Sachs Group restated a “neutral” rating and set a $44.00 target price on shares of Urogen Pharma in a report on Wednesday, July 15th. Guggenheim raised their target price on shares of Urogen Pharma from $32.00 to $42.00 and gave the company a “buy” rating in a report on Tuesday, July 21st. Finally, Oppenheimer lifted their target price on shares of Urogen Pharma from $40.00 to $50.00 and gave the stock an “outperform” rating in a research report on Thursday, July 16th. One analyst has rated the stock with a Strong Buy rating, seven have given a Buy rating, one has given a Hold rating and one has issued a Sell rating to the stock. Based on data from MarketBeat.com, the company presently has an average rating of “Moderate Buy” and an average target price of $41.62.

About Urogen Pharma

UroGen Pharma is a clinical-stage biopharmaceutical company focused on developing and commercializing novel treatments for uro-oncology and uro-genital diseases. Founded in 2010 and headquartered in Ra’anana, Israel, with offices in New York, UroGen applies its proprietary RTGel® reverse thermal gel delivery platform to create sustained-release formulations designed for in-office use by urologists.

The company’s lead product, Jelmyto® (mitomycin gel), received U.S. Food and Drug Administration approval in 2020 for the treatment of adults with low-grade upper tract urothelial cancer.